SCHEMBL1100611

SCHEMBL1100611

N#Cc1cccc(S(=O)(=O)N(CCC2CC2)c2cc3ccccc3s2)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.43
RORC P51449 3/20 0.39
KCNA5 P22460 8/20 0.38
NR1H2 P55055 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
NR1H3 Q13133 1/20 0.35
NPY5R Q15761 1/20 0.35
KCNH2 Q12809 1/20 0.35
JAK2 O60674 1/20 0.35
CASR P41180 1/20 0.34
DPP4 P27487 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099104 0.86 NPY5R (0.41) RORCALDH1A1NPY5R
SCHEMBL1098737 0.85 RORC (0.46) MCOLN3RORCKCNA5NR1H2ALDH1A1
SCHEMBL1100530 0.83 RORC (0.45) MCOLN3RORCKCNA5NR1H2ALDH1A1
SCHEMBL1097937 0.80 NPY5R (0.45) RORCALDH1A1MAPTNPY5R
SCHEMBL1099101 0.80 MCOLN3 (0.45) MCOLN3RORCKCNA5NR1H2NR1H3
SCHEMBL1099917 0.78 RORC (0.41) RORCALDH1A1MAPTNPY5R
SCHEMBL1107258 0.78 HTR2A (0.39) RORCNPY5R
SCHEMBL1099976 0.78 RORC (0.41) RORCALDH1A1NPY5R
SCHEMBL1098414 0.75 TRPM8 (0.46) RORCKCNA5NR1H2
SCHEMBL1099419 0.73 RORC (0.36) RORCNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCOLN3 232/4885RORC 3514/4885KCNA5 64/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCOLN3 232/4885RORC 3514/4885KCNA5 64/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCOLN3 232/4885RORC 3514/4885KCNA5 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.